Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Duvelisib may be taken when the disease has relapsed or is no longer responding to other CLL and SLL treatments
Duvelisib plus venetoclax is a time-limited, all-oral regimen active in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome.
CLL Society would like to make a special request to all of those who have CLL / SLL in our community to please consider submitting a personal comment to the FDA regarding the possibility of duvelisib being removed as an available treatment option.
The days may be numbered for the use of duvelisib, a very effective but potentially toxic oral medication used in CLL / SLL.
The team at Dana-Farber Cancer Institute is testing whether the combination of duvelisib (Copiktra™) and venetoclax (Venclexta®) will lead to deep remissions that would allow for oral only therapy of one year duration. Learn more about this ongoing Phase I/II clinical trial.
ASH 2020: Dr. Jennifer Brown on combination duvelisib + venetoclax for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
There are two approved types of medications that block B cells and lead to excellent control of CLL.
The best known are ibrutinib (Ibrutinib) and acalabrutinib (Calquence) that inhibit the B cell receptor (BCR) downstream by inhibiting BTK.
At ASH 2018, Dr. Matt Davids from Dana Farber Cancer Institute shared some news on duvelisib, the first dual PI3KƔ and ∆ inhibitor that is now approved as third line in
For chronic lymphocytic leukemia patients, it is always good to have more options. The FDA’s approval of duvelisib, a very effective PI3K inhibitor, will be a potent oral monotherapy option for
One click to our most popular content.
